PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis
- 23 September 2024
- journal article
- research article
- Published by Elsevier in Clinical Oncology
- Vol. 36 (12) , 797-808
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerJAMA, 2023
- Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell CarcinomaJAMA Oncology, 2023
- Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patientsCancer, 2021
- Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialGastric Cancer, 2021
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2021
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Microsatellite instability in Gastric Cancer: Between lights and shadowsCancer Treatment Reviews, 2021
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric CancerJAMA Oncology, 2020
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2018
- Oesophageal cancerThe Lancet, 2017